Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2025.May.01

News

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

2025.Apr.29

News

OBI Pharma Unveils New ThiOBI® and HYPrOBI™ Platforms
Showcasing Strong ADC Development Capabilities and Captivating Attention at AACR

2025.Apr.23

News

OBI-822 Completes Second Interim Analysis of Phase III Trial
OBI Announces Trial Termination, Refocuses Resources on ADC Development

Read More

2025.May.06

Announcement

Announcement on behalf of Amaran of not Distributing Dividends of 2024

2025.May.06

Announcement

Announcement on behalf of Amaran that the BOD resolved to convene the 2025 Annual General Shareholders' Meeting

2025.May.01

Announcement

OBI-902 TROP2 ADC has been granted by US FDA to proceed to Phase I/II human clinical trial

2023 Annual Report

Learn how we created value in 2023 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2024 Investors' Meeting - Innovation and Optimism

Download PDFAnnual Report

Read More

2024 Annual Shareholders’ Meeting

  • 2024.Jun.17 at 09:00 AM
  • Masterlink Securities Education and Training Center

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact